Another study found that the absence of pre-existing cfDNA BRCA1/2 reversion mutations in patients with ovarian cancer who had somatic or germline BRCA1/2 mutations and were treated with rucaparib was associated with improved progression-free survival [15]. Here, BRCA1 is linked to ovarian cancer.